drugset / Trial / NCT04599816

Levosimendan Administration in Pulmonary Hypertension

NCT04599816

Completed 45 enrolled Aretaieion University Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The aim of the study is to examine the pharmacokinetics and pharmacodynamic properties of Levosimendan in cardiac surgery patients with pulmonary hypertension and impaired right ventricular function.

Timeline

Start
2020-10-17
Primary completion
2022-10-17
Completion
2022-10-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levosimendan Other / unclassified 3 ug/kg Intravenous
Comparator Levosimendan Other / unclassified 6 ug/kg Intravenous
Comparator Levosimendan Other / unclassified 12 ug/kg Intravenous